22 Republican attorneys general demand mifepristone safety protocols

EXCLUSIVE: More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses “serious risks to women.”

In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations.

“Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of ‘safe’ and ‘effective,'” the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group.

The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a “serious adverse event,” including hemorrhage, emergency room visits and ectopic pregnancy.

FDA CHIEF HAS ‘NO PLANS’ FOR ABORTION PILL POLICY CHANGES BUT CONTINUES SAFETY REVIEW

The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety.

“Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations,” the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place.

“Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,” the attorneys general wrote.

Sen. Josh Hawley, R-Mo., also sent a letter to…